Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOcean Harvest T Regulatory News (OHT)

  • This share is currently suspended. It was suspended at a price of 1.00
  • There is currently no data for OHT

Positive Data on Sow Trial

8 Aug 2024 07:00

RNS Number : 6335Z
Ocean Harvest Technology Group PLC
08 August 2024
 

8 August 2024

Ocean Harvest Technology Group plc

("OHT", the "Company", or the "Group")

Positive data on Sow trial- 5% profitability improvement for customers using OceanFeed Swine. Ocean Harvest Technology Group plc (AIM: OHT), a leading researcher, developer and supplier of proprietary blended seaweed products as functional additives for the global animal feed industry, reports findings of significant benefits from the inclusion of its OceanFeed Swine in Sow diets.

Summary:

· A commercial scale trial at a dedicated research facility of one of OHT's customers has demonstrated that the inclusion of OceanFeed Swine in the diets of pregnant sows has these benefits:

increased the number of piglets born and piglets born alive by 3% and 3.2%, respectively

increased Sow body weight before and after giving birth, improving their resilience

improved milk quality in the first day after birth, which is key to improving the health of the new born piglets

· These results delivered additional revenue of over $24 per Sow per year under current economic conditions, which OHT believes results in an approximate 5% improvement in profit per sow for the groups of sow farming customers it is targeting.

· Management estimate that over $100 billion is spent per annum on feed for Swine and that the opportunity to sell into sows is roughly double the opportunity to sell into piglets. Sales of OceanFeed Swine into piglets represented circa €750,000 of revenue in 2023, showing the substantial growth potential from the commercial application of these results.

The Trial and Results

OHT scoped and funded the trial which involved over 800 sows at the commercial research facility of one of its larger customers, designed to demonstrate the benefits of including OceanFeed Swine in the diets as compared to a standard commercial control diet without OceanFeed Swine. The diets were fed for the duration of the gestation and lactation periods.

OceanFeed Swine increased the number of piglets born and the number of piglets born alive compared with the control diet by 3 and 3.2%, respectively. In addition, the sows supplemented with OFS were heavier at farrowing and weaning compared with sows fed the control diet, and milk quality in the first day after birth was higher in sows fed OFS compared with those fed the control diet.

Commercial Opportunity

The trial resulted in an additional $24 profit per sow from those with OceanFeed Swine included in their diets. This represents a circa 5% profitability improvement for Sow farmers with the profitability profile of the customers OHT is targeting.

OHT believes its opportunity to sell OceanFeed into Sows is roughly double that of its addressable market in nursery piglets. This is because sows in commercial activity are typically pregnant for approximately 41 weeks of each year and consume materially greater volumes of feed than nursery piglets which have smaller diets fed to them for approximately 18 weeks. OHT's piglet sales have been successful for many years and were approximately €750,000, in 2023, hence the larger Sow market is a substantial growth opportunity for OHT.

Mark Williams, CEO of Ocean Harvest Technology Group, commented:

"The performance benefits resulting in a profitability improvement of roughly 5% for the producer in this trial presents OHT with a significant ability to grow its swine business. OHT has been demonstrating for some time how the significant growth, health and performance benefits that its OceanFeed Swine product has when included in the diets of nursery pigs and this commercial-scale trial demonstrates that these health benefits also lead to real commercial benefits in pregnant sows. We believe that this roughly triples OHT's addressable market for its OceanFeed Swine product."

For more information please contact:

Ocean Harvest Technology Group plc

Tel: +44 (0) 1737 735018

 

Mark Williams, CEO

Chris Scott, CFO

 

 

 

 

Cavendish Capital Markets Ltd (Nominated Adviser and Sole Broker)

Tel: +44 020 7220 0500

Geoff Nash / Seamus Fricker / George Dollemore (Corporate Finance)

Tim Redfern / Harriet Ward (ECM)

 

 

 

 

Notes to Editors

 

Ocean Harvest Technology Group plc is a global leader in the development and commercialisation of value adding proprietary products from blending multiple species of seaweed. The Company provides a range of natural additives focused on improving animal performance and the sustainability of the feed chain, through its unique and proven proprietary seaweed blends. The Company sources its seaweed globally, utilising sustainable and socially responsible harvesting of largely wild blooming seaweed species. Its products are produced in its facility in Vietnam and sold into the $40bn animal feed additive sector in multiple markets across the world.

 

For more information, please visit www.oceanharvesttechnology.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKDLFBZVLZBBF
Date   Source Headline
27th Apr 20235:38 pmRNSnotification of major holdings
26th Apr 20237:00 amRNSAppointment to the Board
24th Apr 20237:42 amRNSDirector/PDMR Shareholding
19th Apr 20234:09 pmRNSHolding(s) in Company
18th Apr 20235:45 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSHolding(s) in Company
14th Apr 20234:58 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSInvestor Presentation
5th Apr 20237:00 amRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSAdmission to Trading on AIM
4th Jun 200812:00 pmRNSCancellation of Admission
29th May 20087:45 amRNS1st Quarter Results
1st May 20088:30 amRNSNotice of Special Meeting
10th Mar 20087:45 amRNSRe Contract
3rd Mar 20087:45 amRNSAnnual Report and Accounts
12th Feb 20087:45 amRNSRe Contract
28th Jan 20087:45 amRNSRe. Contract
14th Jan 20087:45 amRNSRe Contract
8th Jan 20087:45 amRNSStaff Appointments
3rd Jan 200810:45 amRNSHolding(s) in Company
27th Dec 200710:28 amRNSDirectorate Change
17th Dec 20077:45 amRNSHolding(s) in Company
4th Dec 20077:45 amRNSRe Contract
26th Nov 200710:48 amRNSRe Contract
12th Nov 20077:00 amRNS3rd Quarter Results
11th Oct 20071:00 pmRNSAGM Statement
20th Aug 20079:24 amRNSInterim Results
15th Aug 20077:01 amRNSCompany Website
7th Aug 20077:00 amRNSRe Contract
1st Aug 20077:00 amRNSRe Contract
19th Jun 20077:02 amRNSRe Contract
15th May 20077:01 amRNS1st Quarter Results
23rd Apr 20077:00 amRNSRe Contract
2nd Apr 20077:01 amRNSRe Contract
13th Mar 20077:00 amRNSAnnual Report and Accounts
20th Feb 20077:00 amRNSRe Contract
4th Dec 20067:00 amRNSRe Contract
21st Nov 20067:00 amRNS3rd Quarter Results
26th Oct 20067:00 amRNSRe Agreement
9th Oct 20067:00 amRNSRe Agreement
5th Oct 20067:00 amRNSRe: Agreement
28th Sep 20063:45 pmRNSDirectorate Change
29th Aug 20067:01 amRNSRe Agreement
15th Aug 20067:00 amRNSInterim Results
16th May 20067:01 amRNS1st Quarter Results
25th Apr 20067:00 amRNSRe Agreement
11th Apr 20067:00 amRNSRe Agreement
20th Mar 20068:00 amRNSRe Agreement
14th Mar 20067:01 amRNSFinal Results
8th Mar 20069:00 amRNSRe Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.